Early results of intra-articular
micro-fragmented lipoaspirate
treatment in patients with late
stages knee osteoarthritis: a
prospective study by Damir Hudetz et al.
227
www.cmj.hr
Aim To analyze clinical and functional effects of intra-ar-
ticular injection of autologous micro-fragmented lipoaspi-
rate (MLA) in patients with late stage knee osteoarthritis 
(KOA). Secondary aims included classifying cell types con-
tributing to the treatment effect, performing detailed MRI-
based classification of KOA, and elucidating the predictors 
for functional outcomes.
Methods This prospective, non-randomized study was 
conducted from June 2016 to February 2018 and enrolled 
20 patients with late stage symptomatic KOA (Kellgren 
Lawrence grade III, n = 4; and IV, n = 16) who received an 
intra-articular injection of autologous MLA in the index 
knee joint. At baseline radiological KOA grade and MRI 
were assessed in order to classify the morphology of KOA 
changes. Stromal vascular fraction cells obtained from 
MLA samples were stained with antibodies specific for cell 
surface markers. Patients were evaluated at baseline and 
12-months after treatment with visual analog scale (VAS), 
Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC), and Knee Injury and Osteoarthritis Out-
come Score (KOOS).
Results Three patients (15%) received a total knee replace-
ment and were not followed up completely. Seventeen 
patients (85%) showed a substantial pattern of KOOS and 
WOMAC improvement, significant in all accounts. KOOS 
score improved from 46 to 176% when compared with 
baseline, WOMAC decreased from 40 to 45%, while VAS rat-
ing decreased from 54% to 82% (all P values were <0.001). 
MLA contained endothelial progenitor cells, pericytes, and 
supra-adventitial adipose stromal cells as most abundant 
cell phenotypes.
Conclusion This study is among the first to show a posi-
tive effect of MLA on patients with late stages KOA.
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Knee osteoarthritis (KOA) is a disabling disease affecting 
around 250 million people worldwide. Risk factors that 
can facilitate KOA include age, genes, environment, and 
local trauma (1,2). Osteoarthritis involves deterioration of 
cartilage, subchondral bone, joint deformities, ligament 
and menisci damage, and surrounding muscle atrophy. 
Magnetic resonance imaging (MRI) enables detecting 
structural changes of KOA. It helps classify KOA according 
to the International Cartilage Repair Society scale in five 
stages, depending on the severity of the chondral lesion 
and surrounding subchondral bone. Runhaar et al (3) have 
demonstrated that MRI can be a valid tool for semiquan-
titative scoring of KOA. Magnetic Resonance Imaging Os-
teoarthritis Knee Score (MOAKS) can be used to quantify 
disease status. The gold standard in the diagnosis of KOA 
is the Kellgren-Lawrence classification. However, there 
are new paradigms in the KOA classification. Dell’Isola et 
al (4) presented a new KOA classification with regard to 
the phenotype. He allocated patients into groups char-
acterized by specific disease mechanisms and analyzed 
their relation with demographic and health outcomes. In 
their study, 599 patients were selected and matched for 
six phenotypes: Minimal Joint Disease, Malaligned Bio-
mechanical, Chronic Pain, Inflammatory, Metabolic Syn-
drome, and Bone and Cartilage Metabolism. The results 
showed that phenotype classification had an effect on 
WOMAC pain and physical function, which could mean 
that selecting patients by phenotype could give us bet-
ter therapy outcomes (4). The complexity of KOA makes 
treatment difficult and partially unpredictable. Conser-
vative approach of KOA treatment deploys non-steroidal 
anti-inflammatory drugs (NSAIDS), intra-articular steroid 
injections, hyaluronic acid, platelet rich plasma, and physi-
cal therapy. Surgical methods include joint preserving sur-
gery for early KOA stages and knee replacement surgery 
for late stages (5-11). Current treatment strategies are a 
form of palliation and are aimed at providing symptomat-
ic pain relief, failing to prevent the disease and/or improve 
tissue structure. However, recent reports on the outcomes 
of cell based therapies show that there is a potential to 
structurally remodel knee joint at a biochemical level, 
contributing to anabolic effects in tissues like bone and 
cartilage rather than to anti-inflammatory mechanisms 
(11-14). Adult mesenchymal stem cells (MSCs) have been 
in the last decade brought under the spotlight for various 
regenerative purposes. Their paracrine activity is thought 
to be one of the major mechanisms by which MSCs in-
hibit ischemia-caused apoptosis, scar formations, stimu-
late angiogenesis, and mediate anti-inflammatory and 
wound healing properties. Biological mediators se-
creted by MSCs provoke complex interaction when they 
regulate various regeneration processes. Pericytes, cells 
present on the micro vessels and capillaries in various tis-
sues, are in vivo precursors of MSCs. Pericytes become ac-
tivated during tissue injury and detach to become MSCs. 
Healing process is a site of busy cell action and interaction, 
initiated by MSCs signaling (15-18).
The application of MSCs in the treatment of early stages 
KOA can bring pain relief, improve knee joint function, and 
influence cartilage status while remaining safe (18-21). The 
aim of this study was to evaluate clinical and functional 
results of an intra-articular injection of autologous micro-
fragmented lipoaspirate (MLA) in patients with severe KOA 
12 months after the treatment. Secondary aims included 
classifying and determining cell types contained in the 
MLA, performing detailed MRI based classification of KOA, 
elucidating predictors for functional outcomes, and de-
termining complication rates. We hypothesized that MLA 
treatment would improve clinical outcomes in patients 
with late stage KOA thus postponing TKR surgery.
PATIEnTS AnD METHODS
This prospective, non-randomized, interventional, single-
center, open-label clinical trial involved patients with pri-
mary late stage KOA who received a single intra-articular 
injection of autologous MLA. Inclusion and exclusion cri-
teria and data collection procedure were the same as in 
our previous study (18). Briefly, the study enrolled patients 
with primary KOA from one center (to which all primary 
KOA patients were referred) who met the inclusion criteria 
(radiological Kellgren Lawrence grade III and IV; onset of 
symptoms of the index knee at six or more months ago; 
ability to follow the study instructions; age 40–85). The 
exclusion criteria were age <40 years or >85 years; chon-
dromatosis or villonodular synovitis of the knee; recent 
trauma (<3 months) of the symptomatic knee; infectious 
joint disease; malignancy; pregnancy; anticoagulant ther-
apy with prothrombin time (<0.70) or thrombocytopenia 
and/or coagulation disorder; and hypersensitivity to local 
anesthetics. Participants underwent detailed clinical histo-
ry-taking, complete physical examination, and radiologi-
cal assessment including plain x-rays (AP standing and LL 
knee projections), full-length weight bearing x-ray in the 
standing position in order to measure limb alignment, and 
MRI. Clinical and functional assessment included the visual 
analog scale (VAS), Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC), and Knee Injury and 
Osteoarthritis Outcome Score (KOOS) pain scale at base-
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line and at 12-months follow-up. Twenty patients were 
enrolled and 20 knees were assessed. Eleven screened pa-
tients were not included because they did not meet enroll-
ment criteria. No patients were excluded from the study. 
After having received detailed written and oral informa-
tion about the study protocol, all patients gave informed 
consent. Each patient who entered the trial received a 
unique anonymous code. Data were collected in the data 
logbook. At baseline, we collected data on primary diag-
noses and medical history, as well as patient demographic 
data (18). The recruitment period lasted from June 2016 to 
February 2017, with the follow-up period ending in Feb-
ruary 2018. All procedures were standardized and imple-
mented according to the standard operating procedure 
protocol. Primary outcome measure was avoiding TKR sur-
gery. Secondary outcome measures were VAS, KOOS, and 
WOMAC results. The study protocol was approved by the 
local Institutional Review Board (IRB authorization No: EP 
001/2016). All the patients were enrolled after IRB approval 
had been obtained and some of them before finalization 
of the ISCRTN registration (February 24, 2017).
KOA radiological classification
The Kellgren-Lawrence grading system classifies the sever-
ity of KOA on standard weight-bearing knee radiographs 
in two planes using five grades: grade 0 – no radiographic 
features of KOA are present; grade 1 – doubtful joint space 
narrowing (JSN) and possible osteophytic lipping; grade 
2 – definite osteophytes and possible JSN on anteropos-
terior weight-bearing radiograph; grade 3 – multiple os-
teophytes, definite JSN, sclerosis, possible bony deformity; 
grade 4 – large osteophytes, marked JSN, severe sclerosis, 
and definitive bony deformity.
The severity of KOA in the study cohort was characterized 
on MRI by an experienced musculoskeletal radiologist (IB) 
using scoring system introduced by International Cartilage 
Research Society based on modified Outerbridge system 
divided in 5 stages according to cartilage lesions size and 
depth, as well as the appearance of the surrounding sub-
chondral bone: grade 0 – normal cartilage; grade 1 – signal 
intensity alterations with an intact surface of the articular 
cartilage compared with the surrounding normal cartilage; 
grade 2 – partial thickness defect of the cartilage with fis-
sures on the surface that do not reach subchondral bone 
or exceed 1.5 cm in diameter; grade 3 – fissuring of the 
cartilage to the level of the subchondral bone in an area 
with a diameter more than 1.5 cm; and grade 4 – exposed 
subchondral bone.
The MR images were performed on a 1.5T magnet (Avanto; 
Siemens, Erlangen, Germany) using a dedicated knee coil 
(Siemens, Erlangen, Germany). Proton density sequenc-
es with fat suppression [TR = 2700 ms; TE = 28 ms; Band-
width = 326Hz; FOV = 170 mm; Matrix = 384 × 384; voxel 
size = 0.4 × 0.4 × 3mm; NEX = 2] in three planes were used 
to evaluate femoral, tibial, and patellar articular cartilage.
The status of cartilage was analyzed on seven different ar-
ticular facets: medial and lateral femoral condyle, femoral 
trochlea, medial and lateral tibial condyle, and both patel-
lar facets.
The presence of meniscal tears was analyzed in three dif-
ferent locations of each meniscus: anterior horn, corpus, 
and posterior horn. Meniscal tear was defined as linear sig-
nal intensity changes that reach meniscal surfaces at least 
2 consecutive MR slices (slice thickness of 3 mm).
Associated subchondral bone marrow edema and joint ef-
fusion were analyzed as a reactive change with knee OA. 
Subchondral bone marrow edema was defined as an ab-
normal fluid signal seen within the bone marrow and joint 
effusion as a fluid signal intensity collection within the 
knee joint space on MRI.
Transplantation and processing of micro-fragmented 
lipoaspirate
The patients were referred to the day surgery unit with 
an average admission of 3 h. The surgical part of the pro-
cedure was set in an operating theater and performed as 
described in our previous study (18). Briefly, patients were 
placed in a supine position; the abdominal skin was treated 
with Dermoguard® antiseptic lotion (Antiseptica, Pulheim, 
Germany), rinsed with Aqua pro injection solution (HZTM, 
Zagreb, Croatia), and dried out and disinfected with Skin-
Des® solution (Antiseptica, Pulheim, Germany). The mini-
mal invasive surgical procedure included an infiltration 
step, in which a total of 250 mL of saline solution pre-
pared with a 40 mL of a 2% lidocaine solution (Lidokain®, 
Belupo, Koprivnica, Croatia) and 1 mL epinephrinhydro-
chloride (1mg/mL) (Suprarenin®, Sanofi-Aventis, Berlin, 
Germany) was injected in the abdominal subcutaneous 
adipose tissue. In the aspiration step, a standard lipoaspi-
ration technique was performed, and the harvested fat 
was introduced into the Lipogems® ortho kit (Lipogems 
International SpA, Milan, Italy) according to the manu-
facturer’s instructions. The collected and processed fi-
nal micro-fragmented adipose tissue product was 
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transferred to 10 mL syringes and injected intra-articularly 
(5 mL) into the index knee.
Stromal vascular fraction (SVF) isolation
Micro-fragmented lipoaspirate (MLA) specimens were 
stored overnight at room temperature (RT) protected from 
light. Samples were then digested with 0.1% collagenase 
type I in DMEM (both from Sigma-Aldrich, Saint Louis, MO, 
USA) in a shaking bath at 37°C for 45 minutes. After a 1:2 
sample dilution with 2% fetal bovine serum (Biosera, Nu-
aille, France) in DMEM, the samples were filtered through a 
100 μm cell strainer (BD Falcon, Corning, NY, USA) and cen-
trifuged at 300 g for 10 minutes at RT. Supernatants were 
discarded and cell pellet was resuspended in 1 mL of the 
VersaLyse solution (Beckman Coulter, Miami, FL, USA). After 
10 minutes, the samples were filtered through a 40 μm cell 
strainer (BD Falcon), centrifuged at 300 g for 10 minutes at 
RT, and the pellet was resuspended in DMEM. Cells were 
counted on the Sysmex XT1800 counter (Sysmex, Kobe, 
Japan).
Flow cytometry
SVF cells obtained from MLA samples of KOA patients were 
stained with antibodies specific for the cell surface mark-
ers: CD31, CD34, CD45, CD73, CD90, CD105, CD146, la-
beled with PB, ECD, APC-AF750, PE, FITC, CD45-PC7, PC5.5 
fluorochromes, respectively (kindly provided by Beckman 
Coulter). In parallel, dead cells were stained with Live/Dead 
Yellow Fixable Stain (ThermoFisher, Waltham, MA, USA). Af-
ter 20 minutes, samples were fixed with 2% paraformalde-
hyde (Electron Microscopy Sciences, Hatfield, PA, USA) in 
PBS (Sigma-Aldrich), washed, and permeabilized with Per-
mWash (BD Biosciences, San Jose, CA, USA). The cell nuclei 
were stained with the DRAQ7 dye (BioStatus, Shepshed, 
UK). The FlowLogic software (Inivai Technologies, Mentone, 
Australia) was used for the analysis of the FCS data files.
TABLE 1. The initial comparison of all Knee Injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) related variables between baseline and 12-months follow up (mean ± standard deviation)
Clinical score Baseline 12-months follow up P (paired) Average percent change
KOOS Pain_1 38.69 ± 17.34 64.57 ± 15.38 <0.001  +66.9
KOOS Symptom_1 47.76 ± 17.88 69.84 ± 15.91 <0.001  +46.2
KOOS ADL_1 39.6 ± 19.5 64.25 ± 17.84 <0.001  +62.2
KOOS Sport/Rec_1 16.25 ± 15.55 34.69 ± 20.85 0.003 +113.5
KOOS QOL_1 13.28 ± 12.68 36.7 ± 19.24 <0.001 +176.4
WOMAC PAIN_1 11.88 ± 3.76  6.5 ± 3.35 <0.001  -45.3
WOMAC STIFFNESS_1  4.31 ± 1.89  2.56 ± 1.46 0.001  -40.6
WOMAC PHYSICAL FUNCTION_1 39.19 ± 14.2 23.19 ± 10.85 <0.001  -40.8
WOMAC TOTAL SCORE_1 55.38 ± 18.83 32.25 ± 14.62 <0.001  -41.8
VAS resting_1  4.06 ± 2.35  0.75 ± 1.65 <0.001  -81.5
VAS movement_1  7.38 ± 1.41  3.38 ± 1.89 <0.001  -54.2
TABLE 2. Forward regression models predicting the extent of change of Knee Injury and Osteoarthritis Outcome Score (KOOS) and 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for pain
KOOS pain Predictor Beta P
Model 1 meniscus injury, lateral meniscus, corpus -0.578 0.038
Model 2 meniscus injury, lateral meniscus, corpus -0.780 <0.001
meniscus injury, medial meniscus, horn -0.709 0.001
Model 3 meniscus injury, lateral meniscus, corpus -0.844 <0.001
meniscus injury, medial meniscus, horn -0.792 <0.001
regular use of NSAID* -0.332 0.014
Model 4 meniscus injury, lateral meniscus, corpus -0.746 <0.001
meniscus injury, medial meniscus, horn -0.855 <0.001
regular use of NSAID -0.369 0.001
bone marrow edema, patellofemoral joint -0.295 0.003
WOMAC pain bone marrow edema, patellofemoral joint -0.668 0.013
*nSAID – nonsteroidal anti-inflammatory drugs.
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Statistical analysis
Descriptive and analytic methods were used. The normali-
ty of distribution was tested by the Shapiro-Wilks test. Data 
are presented as mean and standard deviation. Paired data 
were analyzed using paired t test. We also used a forward 
model of linear regression, where all available clinical pre-
dictors were entered, in an attempt to identify the ones 
that were the most predictive for the outcome variable, in 
this case the change of the KOOS and WOMAC scores. The 
data were analyzed in R (www.r-project.org), with the level 
of significance set at P < 0.05.
RESULTS
Patients’ characteristics
The study enrolled 20 patients who met the inclusion cri-
teria (15 men). Body mass index values were <30 in 13 pa-
tients, 30-35 in 5 patients, and >35 in 2 patients. In 19 pa-
tients, previous treatments (physical therapy, oral NSAIDs, 
or intra-articular injection of hyaluronic acid or steroids) 
had failed to relieve symptoms.
The pattern, distribution, and severity of cartilage tissue 
deterioration, bone marrow edema, effusion, and align-
ment as assessed by x-rays and MRI varied substantially 
at the baseline. Out of 20 knees, in 15 we observed varus 
deformities (>5° malalignment), one valgus knee with (>5° 
malalignment), and 5 knees with good alignment.
Safety of intra-articular injection of autologous micro-
fragmented lipoaspirate
No adverse events (AE) were observed in association with 
lipoaspiration or intra-articular injection. No infectious AEs 
related to intra-articular injection occurred during the fol-
low-up.
FIgURE 1. Summarized results of main imunophenotypes in the stromal vascular fraction (SVF) nucleated cell populations from mi-
crofragmented adipose tissue isolated from 20 osteoarthritic patients. EMC – endothelial mature cells, EPC – endothelial progenitor 
cells, SA-ASC – supra-adventitial adipose stromal cells.
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Clinical outcome
Out of 20 patients, 3 underwent TKA before the end of one-
year period due to persistent high level of symptoms. The 
remaining 17 patients (85%) were analyzed in detail. The 
overall results showed a substantial and universal pattern 
of KOOS and WOMAC improvement, which was significant 
in all accounts (Table 1). In general, KOOS score improved 
by at least half, while WOMAC yielded a similar magnitude 
of decrease (Table 1).
The use of the forward regression model for the KOOS and 
WOMAC, with a number of clinically relevant predictors re-
sulted in a total of five significant models, four for KOOS pain 
and one for WOMAC pain (Table 2). Notably, these two mod-
els overlapped in the bone marrow edema of the anterior 
part of the knee joint between trochlea and patella (Table 2).
Immunophenotyping analysis of stromal vascular 
fraction from micro-fragmented lipoaspirate samples by 
polychromatic flow cytometry
The viability of nucleated CD45- and CD45+ cells in SVF from 
MLA was 95% ± 3.6. Four main CD45- subpopulations were 
CD31-CD34-CD146+ pericytes, CD31-CD34+CD146- supra-
adventitial adipose stromal cells (SA-ASC), CD31+CD34+ 
endothelial progenitor cells (EPC), and CD31+CD34- ma-
ture endothelial cells (EM) (Figure 1). The determined sub-
populations showed variable levels of the mesenchymal 
markers CD73, CD90, and CD105 (Polancec et al, unpub-
lished data).
DISCUSSIOn
In this study, we reported the results for 20 patients with 
late stages KOA receiving intra-articular micro-fragmented 
autologous fat tissue transplantation. Patients included in 
the study had grade III and IV KOA with high level of symp-
toms and pain at the baseline. Before study enrollment, all 
the patients had been candidates for a TKR surgery. Our 
study showed that MLA treatment relieved pain and clinical 
symptoms in 85% of patients with late stages KOA for one 
year. We should emphasize that there are only a few studies 
that showed a positive effect of adipose tissue-originated 
mesenchymal stem cells (Ad-MSCs) on patients with high 
grade KOA. The results of our study are in line with the re-
sults of some previous studies. Koh et al (22) found that Ad-
MSCs exhibited effects on cartilage healing, reduced pain, 
FIgURE 2. Pericytes are stimulated by soluble growth factors and chemokines to become activated mesenchymal stem cells (MSCs), 
and probably in interaction with endothelial progenitors both cell types respond to the microenvironment by secreting trophic 
(mitogenic, angiogenic, anti-apoptotic, or scar reduction), immunomodulatory or antimicrobial factors. After the microenvironment 
is re-established, MSCs return to their native pericyte state attached to blood vessels. SVF – stromal vascular fraction. Murphy BM, 
Moncivais K and Caplan IA. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimen-
tal and Molecular Medicine (2013) 45, e54; doi:10.1038/emm.2013.94 (Used and adapted with permission of Prof. Arnold I Caplan 
and publisher’s permission).
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and improved function in KOA patients evaluated by sec-
ond look arthroscopy and clinical outcome scores. Jo et al 
(23) concluded that intra-articular injections of Ad-MSCs in 
KOA improved function and reduced cartilage defects. The 
study of Yokota et al (24) involved 13 patients (11 OA grade 
IV and 2 OA grade II according Kellgren-Lawrence scale). 
Based on the VAS, Japanese Knee Osteoarthritis Measure, 
and WOMAC score they found a significant improvement 
in the first month after the procedure and a small numeri-
cal improvement after six months. The results obtained in 
our study provide a good basis for prospective randomized 
controlled clinical trials with the aim to evaluate the use 
of autologous MLA containing Ad-MSCs in the treatment 
of higher-grade KOA. Before adipose tissue microfragmen-
tation was established, mechanical procedures had been 
considered as low-yield methods for obtaining SVF com-
pared with enzymatic methods (25). However, MLA is rich 
in SVF cells with high regenerative capacity, as confirmed 
in our study.
Our study suggests that application of autologuos micro-
fragmented adipose tissue with SVF in patients with KOA 
increases GAG levels in hyaline cartilage, consequently re-
ducing pain and improving movement abilities (18). SVF 
from adipose tissue contains SA-ASC, pericytes, EPC, EMC, 
and leukocytes. There are at least two possible mechanisms 
through which MSCs exert their effect and that might ex-
plain the success of SVF-treatment of KOA. The first one as-
sumes that MSCs differentiate into chondrocytes, while the 
second one suggests that MSCs stimulate chondrocytes 
by paracrine secretion of bioactive factors. As our results 
revealed that SVF contained a respectable ratio of EPC (Po-
lancec et al., unpublished data), this sheds a new light on 
the MSC-mediated cartilage tissue repair and regeneration 
that assumes cooperation with EPC. EPC represent impor-
tant players implicated in vascularization as a prerequisite 
for wound repair and tissue regeneration (26,27). Several 
in vitro and in vivo studies have demonstrated proliferative, 
proangiogenic, and vasculogenic effects of MSC-EPC in-
teractions (28-31), as well as differentiation commitment 
(32,33). A crosstalk between MSC-EPC, which can involve 
both paracrine mechanism and/or cell-cell contact (via 
PDGF-PDGFR and Notch-signaling) (29,34), seems to occur 
in different conditions of tissue inflammation (35), suggest-
ing their interplay and beneficial effects also in cartilage 
tissue repair and regeneration. The fact that in our study 
EPCs outnumber MSCs indicates their inevitable involve-
ment in the observed effect of the SVF-mediated cartilage 
treatment. Therefore, we hypothesize that a plethora of cy-
tokines, chemokines, and growth factors, ie, bioactive mol-
ecules hitherto ascribed to the activated MSC, acting as 
medicinal signaling cells (36), perhaps stem from a syner-
gistic effect of pericyte-MSC-EPC interactions (Figure 2).
Osteoarthritis primarily affects cartilage tissue, which is 
best diagnosed and described by MRI. However, radiogra-
phy with standard x-rays is limited when it comes to rec-
ognizing early degenerative changes. The delayed gad-
olinium-enhanced MRI of cartilage technique assessing 
proteoglycan content has shown potential in evaluating 
the macromolecular status of normal, degenerated, and 
regenerated articular cartilage (18). Runhaar et al showed 
that MRI imaging can be a valid tool for semiquantitative 
scoring of KOA. MOAKS is primarily applicable to quantify 
disease status, which could lead to better treatment out-
comes (3). Five Kellgren-Lawrence stages based on AP 
weight bearing x-rays merely describe pathological chang-
es that a joint undergoes over time but do not provide a 
sufficient insight into treatment allocation. Dell’Isola et al 
(4) suggested a new classification based on phenotypes. 
All patients (599) were classified into predefined groups 
characterized by specific variables and assigned pheno-
type. At baseline and after 24 months WOMAC score was 
assessed. Both, WOMAC pain and physical function have 
been influenced by KOA phenotype. Assigning a pheno-
type to patients could improve clinical decision making 
and optimal treatment strategies (4). In our study, we used 
MRI to describe KOA morphology by assessing cartilage 
damage, bone marrow edema appearance and distribu-
tion, joint effusion, and location of the meniscus rupture. In 
our attempt to define KOA phenotype more accurately, we 
showed an association between baseline parameters and 
treatment results. Bone marrow edema noted on the knee 
MRI scans at baseline was shown to be a good predictor 
at both KOOS and WOMAC subscales for pain in terms of 
improvement after one year. In our previous study, appli-
cation of MLA increased GAG content (18,37,38), implicat-
ing an effect on patellofemoral joint that bears high shear 
force loads. It has been shown that lipoaspirate with MSCs 
along with platelet-rich plasma has a positive effect in an 
early stage patellofemoral joint OA (39). Paracrine effect of 
cells from micro-fragmented fat tissue on chondrocytes to 
produce extracellular matrix might influence the quality of 
subchondral bone in patellofemoral joint, thus relieving 
pain captured by WOMAC and KOOS pain subscales. Re-
cent results have shown that MLA has a long-lasting anti-
inflammatory property, most likely influenced by a com-
bination of cytokines secreted by SVF cells, primarily by 
MSCs (40). MLA is not a mechanically obtained SVF, it 
can serve as a natural scaffold for drug delivery (41). 
11th ISABS CONFERENCE234 Croat Med J. 2019;60:227-36
www.cmj.hr
Even though we presented significant results, it has to be 
acknowledged that our study has certain limitations par-
ticularly due to a lack of a control group.
In conclusion, the present prospective study suggests that 
intra-articular injection of micro-fragmented fat tissue de-
creases clinical symptoms in patients with late stage KOA, 
without observed AE. Additional randomized clinical stud-
ies are warranted to improve clinical practice especially re-
lated to different KOA phenotypes.
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